EYENOVIA INC. - COMMO

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

23 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

16 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

01 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

27 9 2024 08:30:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

26 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

03 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Closing of Public Offering

23 8 2024 11:42:23 提供 Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5.14 Million Public Offering

21 8 2024 09:29:09 提供 Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Proposed Public Offering

20 8 2024 17:09:50 提供 Nasdaq GlobeNewswire

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

13 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

08 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 8 2024 17:11:42 提供 Nasdaq GlobeNewswire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

23 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5M Registered Direct Offering

28 6 2024 08:00:14 提供 Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

15 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

14 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25 4 2024 07:00:01 提供 Nasdaq GlobeNewswire